Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: Clinical efficacy, safety, pharmacokinetics and pharmacodynamics

International Journal of Antimicrobial Agents

Volumn 25, Issue 6, 2005, Pages 514-522

  Munckhof, Wendy J ^a   Carney, John ^a   Neilson, Gail ^a   Neilson, John ^a   Carroll, Julia ^a   McWhinney, Brett ^a   Whitby, Michael ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Beta lactam; Continuous infusion; Home intravenous therapy

Indexed keywords

TIMENTIN;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; CELLULITIS; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; FEBRILE NEUTROPENIA; FEMALE; HOME CARE; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OSTEOMYELITIS; PRIORITY JOURNAL; RASH; STEADY STATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLAVULANIC ACIDS; FEMALE; HOME INFUSION THERAPY; HUMANS; MALE; MIDDLE AGED; TICARCILLIN; TREATMENT OUTCOME;

EID: 19544372089     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.02.008     Document Type: Article

References (36)

1. J.D. Turnidge The pharmacodynamics of beta-lactams Clin Infect Dis 27 1998 10 22
2. W.A. Craig, and S.C. Ebert Continuous-infusion of beta-lactam antibiotics Antimicrob Agents Chemother 36 1992 2577 2583
3. T.G. Vondracek Beta-lactam antibiotics: is continuous infusion the preferred method of administration? Ann Pharmacother 29 1995 415 424
4. J.L. Kuti, C.H. Nightingale, and R. Quintiliani Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis Diagn Microbiol Infect Dis 44 2002 51 57
5. A.A. Vinks, J.G. den Hollander, and S.E. Overbeek Population pharmacokinetic analysis of nonlinear behaviour of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis Antimicrob Agents Chemother 47 2003 541 547
6. GK. McEvoy AHFS drug information 2003 American Society of Health-System Pharmacists 2003 Bethesda, United States
7. C. Martin, M.N. Mallet, and B. Sastre Comparison of concentrations of two doses of clavulanic acid (200 and 400 milligrams) administered with amoxicillin (2,000 milligrams) in tissues of patients undergoing colorectal surgery Antimicrob Agents Chemother 39 1995 94 98
8. Performance standards for antimicrobial susceptibility testing: 13th informational supplement. National Committee for Clinical Laboratory Standards document M100-S13 (M7). Villanova, PA: National Committee for Clinical Laboratory Standards; January 2003.
9. B.E. Scully, N.X. Chin, and H.C. Neu Pharmacology of ticarcillin compared with clavulanic acid in humans Am J Med 79 Suppl. 5B 1985 S39 S43
10. W.A. Craig, and S.C. Ebert Protein binding and its significance in antibacterial therapy Infect Dis Clin N Am 3 1989 407 414
11. R. Sutherland, J. Burnett, and G.N. Rolinson X-carboxy-3- thienylmethylpenicillin (BRL 2288), a new semisynthetic penicillin: in vitro evaluation Antimicrob Agent Chemother 1 1971 390
12. T. Bergan, W. Olszewski, and A. Engeset Penetration to peripheral human lymph of clavulanic acid and ticarcillin J Antimicrob Chemother 17 1986 97
13. L.G. Visser, P. Arnouts, and R. van Furth Clinical pharmacokinetics of continuous intravenous administration of penicillins Clin Infect Dis 17 1992 491 495
14. A.A.T.M.M. Vinks, R.W. Brimicombe, and H.G.M. Heijerman Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics J Antimicrob Chemother 40 1997 125 133
15. K. Leder, J.D. Turnidge, and T.M. Korman The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis J Antimicrob Chemother 43 1999 113 118
16. J. Berkhout, L.G. Visser, and P.J. van den Broek Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion Antimcrob Agents Chemother 47 2003 1862 1866
17. E. Boselli, D. Breilh, and F. Duflo Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with nosocomial pneumonia Crit Care Med 31 2003 2102 2106
18. A.A. Vinks, J.G. Den Hollander, and S.E. Overbeek Population pharmacokinetic analysis of nonlinear behaviour of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis Antimicrob Agents Chemother 47 2003 541 547
19. K. Bui, P. Ambrose, and E. Grant Pharmacokinetic and pharmacoeconomic evaluation of ticarcillin-clavulanate administered as either continuous or intermittent infusion with once-daily gentamicin Infect Dis Clin Pract 8 1999 449 455
20. D.S. Burgess, and T. Waldrep Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing Clin Ther 24 2002 1090 1104
21. Performance standards for antimicrobial susceptibility testing, 9th informational supplement. M100-S9. Wayne, PA: National Committee for Clinical Laboratory Standards; 1999.
22. T.D. Moore, R. Horton, and L.J. Utrup Stability of amoxicillin- clavulanate in BACTEC medium determined by high-performance liquid chromatography and bioassay J Clin Microbiol 34 1996 1321 1322
23. P.A. Hunter, K. Coleman, and J. Fisher In vitro synergistic properties of clavulanic acid, with ampicillin, amoxicillin and ticarcillin J Antimicrob Chemother 6 1980 455
24. H. Neu, and K. Fu Clavulanic acid, a novel inhibitor of beta-lactamase Antimicrob Agents Chemother 14 1978 650 655
25. R. Wise, J.M. Andrews, and K.A. Bedford In vitro study of clavulanic acid in combination with penicillin, amoxicillin, and carbenicillin Antimicrob Agents Chemother 13 1978 389 393
26. R. Wise, J.M. Andrews, and K.A. Bedford Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins J Antimicrob Chemother 6 1980 197 206
27. C.E. Cooper, B. Slocombe, and A.R. White Effect of low concentrations of clavulanic acid on the in vitro activity of amoxycillin against beta-lactamase-producing Branhemella catarrhalis and Haemophilus influenzae J Antimicrob Chemother 26 1990 371 380
28. I.M. Gould, J. Dent, and R. Wise In vitro bacterial killing kinetics of ticarcillin-clavulanic acid J Antimicrob Chemother 19 1987 307 312
29. M. Dudley Combination beta-lactam and beta-lactamase inhibitor therapy: pharmacokinetic and pharmacodynamic considerations Am J Health Syst Pharm 52 Suppl. 2 1995 S23 S28
30. R. Sutherland, A.S. Beale, and R.J. Boon Antibacterial activity of ticarcillin in the presence of clavulanate potassium Am J Med 79 Suppl. 5B 1985 13 24
31. K. Bush, and R.B. Sykes Beta-lactamase inhibitors in perspective J Antimicrob Chemother 11 1983 97 107
32. M.S. Maddux Effects of beta-lactamase-mediated antimicrobial resistance: the role of beta-lactamase inhibitors Pharmacotherapy 11 1991 40S 50S
33. D.M. Livermore Determinants of the activity of beta-lactamase inhibitor combinations J Antimicrob Chemother 31 Suppl. A 1993 9 21
34. M. Hilf, V.L. Yu, and J. Sharp Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients Am J Med 87 1989 540 546
35. J.A. Korvick, and V.L. Yu Antimicrobial agent therapy for Pseudomonas aeruginosa Antimicrob Agents Chemother 35 1991 2167 2172
36. Australian hospital statistics 2002-3. AIHW cat. no. HSE 32, Health services series no. 22. Canberra, Australia: Australian Institute of Health and Welfare (AIHW); 2004.